US FDA Import Alert and Automatic Detention

A US FDA import alert places a specific product category, exporting country, or named establishment onto a watch list triggering automatic detention without physical examination, meaning every subsequent shipment matching the alert's criteria is held at the US border by default and released only if the importer provides private laboratory testing or other evidence demonstrating that specific shipment is not in violation, shifting the burden of proof onto the importer rather than requiring FDA to find a violation in each individual shipment before acting. Import alerts are typically issued after a pattern of violations is detected, repeated findings of an unapproved drug residue, filth, or microbiological contamination from a specific country or facility, rather than from a single isolated incident, and once issued they apply broadly to the named category until the responsible exporter or country demonstrates, through a formal petition process with supporting testing data, that the underlying problem has been corrected. Being placed on an import alert carries a severe commercial consequence distinct from the cost of any single detained shipment, since automatic detention adds significant delay, cold-chain risk, and testing cost to every subsequent shipment until removed, often prompting affected exporters to invest heavily in corrective action specifically to qualify for an expedited removal review. The FDA publishes its active import alert list publicly, making it a standard due-diligence reference for US importers and international buyers assessing supplier risk before committing to a sourcing relationship with a given country or specific processing facility.